Pink SheetWith the proposed BIOSECURE Act in the US having moved to the Senate for a vote since the US House of Representatives passed related bill HR 8333 on 9 September, there is still lingering uncertainty o
Pink SheetBiopharma firms are rethinking their contract development and manufacturing organization (CDMO) network against the backdrop of geopolitical tensions and the advancement of the US BIOSECURE Act, but t
ScripBiopharma firms are rethinking their contract development and manufacturing organization (CDMO) network against the backdrop of geopolitical tensions and the advancement of the US BIOSECURE legislatio
Pink SheetOnce considered almost inevitable, the passage of BIOSECURE – the US legislation aiming at limiting the involvement of Chinese contract development and manufacturing firms in the biotech industry – no